CompletedPhase 4ACTRN12605000488606

The Chariot Study

A Phase IV, Randomised, Multi-centre, Efficacy and Safety Study Examining the Effect of Induction Dosing with the combination of peginterferon Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Infected with Hepatitis C Genotype 1.

Sponsor

Roche Products Pty Ltd

Enrollment

816 participants

Start Date

Feb 2, 2009

Study Type

Interventional

Conditions

Chronic Hepatitis C genotype 1

Summary

The purpose of the study is to compare the effectiveness of two treatment regimens in clearing the Hepatitis C Virus in patients infected with Hepatitis C genotype 1. The study aims to determine whether a higher dose of pegylated interferon given in combination with ribavirin for the first 12 weeks of therapy results in a higher rate of viral clearance and whether it is safe and tolerable.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 75 Yearss

Plain Language Summary

Simplified for easier understanding

This trial, called the Chariot Study, tests a treatment for chronic hepatitis C infection. Adults aged 18 to 75 with confirmed chronic hepatitis C are eligible. Participation involves receiving antiviral treatment with pegylated interferon and ribavirin and regular blood tests to monitor the virus.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Pegylated interferon alfa 2a and ribavirin for 48 weeks.

Locations(1)

NSW,QLD,SA,WA,VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000488606